Argenx announced an agreement to acquire a FDA Priority Review Voucher, or PRV, for $102M. A PRV entitles the holder to FDA priority review of a single biologics license application, or BLA, which reduces the target review period and may lead to an expedited approval. Argenx expects to redeem the PRV for a future marketing application for efgartigimod, its first-in-class neonatal Fc receptor blocker.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARGX:
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- Argenx price target raised to EUR 480 from EUR 470 at JPMorgan
- argenx to Present at Upcoming Investor Conferences
- argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022